(HealthDay News) — The American Society of Clinical Oncology (ASCO) has endorsed the American Cancer Society (ACS) Prostate Cancer Survivorship Care Guidelines, according to a report published online Feb. 9 in the Journal of Clinical Oncology.
Matthew J. Resnick, M.D., of Vanderbilt University in Nashville, Tenn., and colleagues on the ASCO Endorsement Panel reviewed the content and recommendations in the prostate cancer survivorship guidelines. When deemed necessary, the panel offered modifications and/or qualifying statements.
The ASCO Endorsement Panel found that despite the limited availability of high-quality evidence to support many of the recommendations, the 2014 ACS Prostate Cancer Survivorship Care Guidelines are clear, thorough, and relevant.
In survivors of prostate cancer, prostate-specific antigen (PSA) level should be measured every 6 to 12 months for the first 5 years, then annually. More frequent evaluation may be warranted in men at high risk for recurrence and in candidates for salvage therapy. Survivors with elevated or increasing PSA levels should be referred to their primary treating physician for evaluation and management. ACS guidelines for the early detection of cancer should be followed. Additional recommendations address the assessment of information needs and the physical and psychosocial effects, and long-term or late effects, of prostate cancer and its treatment.
“ASCO endorses the ACS Prostate Cancer Survivorship Care Guidelines, with a number of qualifying statements and modifications,” the authors write.
Several panelists disclosed financial ties to pharmaceutical and/or biomedical companies.